Revolution Medicines, Inc. Common Stock (RVMD) is a publicly traded Healthcare sector company. As of May 21, 2026, RVMD trades at $150.91 with a market cap of $30.69B and a P/E ratio of -24.94. RVMD moved +1.94% today. Year to date, RVMD is +91.92%; over the trailing twelve months it is +271.46%. Its 52-week range spans $29.17 to $155.70. Analyst consensus is strong buy with an average price target of $176.95. Rallies surfaces RVMD's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
RVMD slides after Needham target cut tied to raised 2026 cost guidance: Needham cut its price target on Revolution Medicines to $183, citing higher 2026 costs after updated equity compensation and raised operating-expense guidance. The move follows the company’s Q1 2026 results and earnings call, which highlighted increased stock-based compensation and a larger net loss.
| Metric | Value |
|---|---|
| Price | $150.91 |
| Market Cap | $30.69B |
| P/E Ratio | -24.94 |
| EPS | $-5.95 |
| Dividend Yield | 0.00% |
| 52-Week High | $155.70 |
| 52-Week Low | $29.17 |
| Volume | 2.04M |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-1.13B |
| Gross Margin | 0.00% |
20 analysts cover RVMD: 0 strong buy, 20 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $176.95.